World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2–3 and screen‐and‐treat strategies to prevent cervical cancer

It is estimated that 1%–2% of women develop cervical intraepithelial neoplasia grade 2–3 (CIN 2–3) annually worldwide. The prevalence among women living with HIV is higher, at 10%. If left untreated, CIN 2–3 can progress to cervical cancer. WHO has previously published guidelines for strategies to screen and treat precancerous cervical lesions and for treatment of histologically confirmed CIN 2–3.

[1]  Nancy Santesso,et al.  World Health Organization Guidelines: Use of cryotherapy for cervical intraepithelial neoplasia , 2012, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[2]  Julian Peto,et al.  Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. , 2012, Vaccine.

[3]  R. Sankaranarayanan,et al.  Screening of cervical neoplasia in HIV-infected women in India , 2013, AIDS.

[4]  K. Lakshmaiah,et al.  HPV screening for cervical cancer in rural India. , 2009, The New England journal of medicine.

[5]  E. Lynge,et al.  What women want. Women’s preferences for the management of low‐grade abnormal cervical screening tests: a systematic review , 2012, BJOG : an international journal of obstetrics and gynaecology.

[6]  L. Myer,et al.  Human Papillomavirus Infection and Cervical Disease in Human Immunodeficiency Virus-1–Infected Women , 2008, Obstetrics and gynecology.

[7]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[8]  B. Chan,et al.  Management of the low-grade abnormal Pap smear: What are women's preferences? , 2002, The Journal of family practice.

[9]  S. White,et al.  Women's Perspectives on Cervical Screening and Treatment in Developing Countries: Experiences with New Technologies and Service Delivery Strategies , 2006, Women & health.

[10]  Y. Qiao,et al.  HPV prevalence and cervical intraepithelial neoplasia among HIV-infected women in Yunnan Province, China: a pilot study. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[11]  Z. Chirenje,et al.  A randomised clinical trial of loop electrosurgical excision procedure (LEEP) versus cryotherapy in the treatment of cervical intraepithelial neoplasia. , 2001, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[12]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[13]  H. Schünemann,et al.  Systematic reviews and meta‐analyses of benefits and harms of cryotherapy, LEEP, and cold knife conization to treat cervical intraepithelial neoplasia , 2016, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[14]  W. Tsai,et al.  Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. , 2010, Journal of the National Cancer Institute.

[15]  Reem A. Mustafa,et al.  Systematic reviews and meta‐analyses of the accuracy of HPV tests, visual inspection with acetic acid, cytology, and colposcopy , 2016, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[16]  S. Franceschi,et al.  Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya , 2012, British Journal of Cancer.

[17]  Nancy Santesso,et al.  Cytology versus HPV testing for cervical cancer screening in the general population. , 2017, The Cochrane database of systematic reviews.